Neos Therapeutics to Participate in Three September Conferences
August 30 2017 - 7:30AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery and orally disintegrating tablet
(ODT) technology platforms, today announced that Vipin Garg, Ph.D.,
president and chief executive officer will present a business
overview and update at the following two upcoming September
conferences:
- Wells Fargo 2017 Healthcare Conference at 3:00 p.m. E.T. on
Wednesday, September 6, 2017 in Boston, MA
- Cantor Fitzgerald Global Healthcare Conference at 8:35 a.m.
E.T. on Tuesday, September 26, 2017 in New York, NY
A live audio webcast of both events will be
available on the Investor Relations page of the company’s website
at http://investors.neostx.com/. An archived replay of the webcast
will be available for 30 days after the live event concludes.
Neos management will also be available for
one-on-one meetings at the Mizuho Biotechnology Conference 2017 on
Tuesday, September 19, 2017 in Boston, MA.
About Neos TherapeuticsNeos
Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing
its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODT®, indicated for the treatment of ADHD in
patients 6 years of age and older, and Cotempla XR-ODTTM, indicated
for the treatment of ADHD in patients 6 to 17 years old, are the
first approved products using the Company’s extended-release
(XR)-orally disintegrating tablet (ODT) technology platform. Neos,
which is initially focusing on the treatment of ADHD, has filed New
Drug Applications with the U.S. Food and Drug Administration for
one other branded product candidate that is an XR medication in
oral suspension dosage form. In addition, Neos manufactures and
markets its generic equivalent of the branded product Tussionex®,
an XR oral suspension of hydrocodone and chlorpheniramine indicated
for the relief of cough and upper respiratory symptoms of a
cold.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024